A Randomized Comparison of Once Versus Twice Daily rhG-CSF (Filgrastim) for Stem Cell Mobilisation in Healthy Donors for Allogeneic Transplantation

[1]  C. Waller,et al.  High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  I. Benet,et al.  Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation , 1998, Bone Marrow Transplantation.

[3]  N. Schmitz,et al.  Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation , 1998, Bone Marrow Transplantation.

[4]  N. Kröger,et al.  Schedule-dependency of granulocyte colony-stimulating factor in peripheral blood progenitor cell mobilization in breast cancer patients. , 1998, Blood.

[5]  B. McAneny,et al.  Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim , 1998, British journal of haematology.

[6]  J. Dipersio,et al.  Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Nakayama,et al.  G-CSF-induced mobilization of peripheral blood stem cells for allografting: comparative study of daily single versus divided dose of G-CSF. , 1997, International journal of hematology.

[8]  A. Zander,et al.  Comparison between Bone Marrow and G‐CSF‐Mobilized Peripheral Blood Allografts Undergoing Clinical Scale CD34+ Cell Selection , 1996, Stem cells.

[9]  R. Champlin,et al.  Clinical toxicity and laboratory effects of granulocyte‐colony‐ stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures , 1996, Transfusion.

[10]  N. Schmitz,et al.  THE PLACE OF BLOOD STEM CELLS IN ALLOGENEIC TRANSPLANTATION , 1996, British journal of haematology.

[11]  D. Sutherland,et al.  The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. , 1996, Journal of hematotherapy.

[12]  N. Kröger,et al.  Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. , 1996, Bone marrow transplantation.

[13]  A. Roberts,et al.  Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. , 1995, Blood.

[14]  M. Andreeff,et al.  Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. , 1995, Blood.

[15]  M. Harada,et al.  Granulocyte colony-stimulating factor mobilizes primitive hematopoietic stem cells in normal individuals. , 1995, Bone marrow transplantation.

[16]  R. Storb,et al.  Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor , 1995 .

[17]  A. Deisseroth,et al.  Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts , 1995 .

[18]  C. Hack,et al.  Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. , 1994, Blood.

[19]  N. Schmitz,et al.  G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft , 1994, British journal of haematology.